Angiogenesis in head and neck cancer: A review of the literature

Journal of Oncology

Volumn , Issue , 2012, Pages

  Carla, Codecà ^a   Daris, Ferrari ^a   Cecilia, Bertuzzi ^a   Francesca, Broggio ^a   Francesca, Crepaldi ^a   Paolo, Foa ^a  

^a Division of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; PACLITAXEL; SORAFENIB; SUNITINIB; THALIDOMIDE; VATALANIB;

ALLERGIC RASH; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; BRAIN ISCHEMIA; CANCER GROWTH; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; HYPONATREMIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DERMATITIS; REVIEW; STOMATITIS; STROKE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TUMOR BLEEDING; TUMOR VASCULARIZATION; VOMITING;

EID: 84855257672     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/358472     Document Type: Review

References (88)

1. Davies L., Welch H. G., Epidemiology of head and neck cancer in the United States Otolaryngology-Head Neck Surgery 2006 135 3 451 457
2. Forastiere A. A., Trotti A., Pfister D. G., Grandis J. R., Head and neck cancer: recent advances and new standards of care Journal of Clinical Oncology 2006 10 17 2603 2605 (Pubitemid 46622079)
3. Vermorken J., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H. R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R., Platinum-based chemotherapy plus cetuximab in head and neck cancer New England Journal of Medicine 2008 359 11 1116 1127
4. Christopoulos A., Ahn S. M., Klein J. D., Seungwon Kim. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis Head and Neck 2011 33 8 1220 1229
5. Maxwell P. H., Wlesener M. S., Chang G. W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 1999 399 6733 271 275 (Pubitemid 29246458)
6. Hicklin D. J., Ellis L. M., Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis Journal of Clinical Oncology 2005 23 5 1011 1027 (Pubitemid 46202320)
7. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors Nature Medicine 2003 9 6 669 676 (Pubitemid 36749215)
8. Holmes K., Roberts O. L., Thomas A. M., Cross M. J., Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition Cellular Signalling 2007 19 10 2003 2012 (Pubitemid 47354167)
9. Ellis L. M., The role of neuropilins in cancer Molecular Cancer Therapeutics 2006 5 5 1099 1107 (Pubitemid 43881301)
10. Riedel F., Gtte K., Schwalb J., Wirtz H., Bergler W., Hrmann K., Serum levels of vascular endothelial growth factor in patients with head and neck cancer European Archives of Oto-Rhino-Laryngology 2000 257 6 332 336 (Pubitemid 30612326)
11. Shemirani B., Crowe D. L., Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors Oral Oncology 2000 36 1 61 66
12. Smith B. D., Smith G. L., Carter D., Sasaki C. T., Haffty B. G., Prognostic significance of Vascular Endothelial Growth Factor protein levels in oral and oropharyngeal squamous cell carcinoma Journal of Clinical Oncology 2000 18 10 2046 2052 (Pubitemid 30324357)
13. Lentsch E. J., Goudy S., Sosnowski J., Major S., Bumpous J. M., Microvessel density in head and neck squamous cell carcinoma primary tumors and its correlation with clinical staging parameters Laryngoscope 2006 116 3 397 400 (Pubitemid 44318099)
14. Moriyama M., Kumagai S., Kawashiri S., Kojima K., Kakihara K., Yamamoto E., Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma Oral Oncology 1997 33 5 369 374 (Pubitemid 28129241)
15. Boonkitticharoen V., Kulapaditharom B., Leopairut J., Kraiphibul P., Larbcharoensub N., Cheewaruangroj W., Chintrakarn C., Pochanukul L., Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma Archives of Otolaryngology: Head and Neck Surgery 2008 134 12 1305 1311
16. Tse G., Chan A., Yu K., King A. D., Wong K. T., Chen G. G., Tsang R. K. Y., Chan A. B. W., Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma Annals of Surgical Oncology 2007 14 12 3558 3565 (Pubitemid 350160145)
17. Kyzas P. A., Cunha I. W., Ioannidis J. P., Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis Clinical Cancer Research 2005 11 4 1434 1440 (Pubitemid 40315223)
18. Hasina R., Whipple M., Martin L., Kuo W. P., Ohno-Machado L., Lingen M. W., Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications Laboratory Investigation 2008 88 4 342 353 (Pubitemid 351432778)
19. Miyazawa M., Dong Z., Zhang Z., Neiva K. G., Cordeiro M. M., Oliveira D. T., Nor J. E., Effect of PTK/ZK on the angiogenic switch in head and neck tumors Journal of Dental Research 2008 87 12 1166 1171
20. Hess-Stunnpp H., Haberey M., Thierauch K. H., PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy ChemBioChem 2005 6 3 550 557 (Pubitemid 40868144)
21. Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Muller M., Wood J., Martiny-Baron G., Unger C., Marme D., Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model Cancer Research 2000 60 17 4819 4824
22. Kim S., Yazici Y. D., Barber S. E., Jasser S. A., Mandal M., Bekele B. N., Myers J. N., Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11 Head and Neck 2006 28 5 389 399 (Pubitemid 43673073)
23. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., De Placido S., Bianco A. R., Tortora G., Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clinical Cancer Research 2001 7 5 1459 1465 (Pubitemid 32708703)
24. Jung Y. D., Mansfield P. F., Akagi M., Takeda A., Liu W., Bucana C. D., Hicklin D. J., Ellis L. M., Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model European Journal of Cancer 2002 38 8 1133 1140 (Pubitemid 34468020)
25. Herbst R. S., Mininberg E., Henderson T., Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCI as targeted cancer therapy in patients with recurrent non-small cell lung cancer European Journal of Cancer 2003 1 S293
26. Wachsberger P. R., Burd R., Marero N., Daskalakis C., Ryan A., McCue P., Dicker A. P., Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma Clinical Cancer Research 2005 11 2 I 835 842 (Pubitemid 40116912)
27. Nieder C., Wiedenmann N., Andratschke N., Molls M., Current status of angiogenesis inhibitors combined with radiation therapy Cancer Treatment Reviews 2006 32 5 348 364 (Pubitemid 44063875)
28. Bonner J. A., Harari P. M., Giralt J., Azarnia N., Shin D. M., Cohen R. B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M. S., Baselga J., Youssoufian H., Amellal N., Rowinsky E. K., Ang K. K., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck New England Journal of Medicine 2006 354 6 567 578 (Pubitemid 43209104)
29. Bozec A., Formento P., Lassalle S., Lippens C., Hofman P., Milano G., Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts British Journal of Cancer 2007 97 1 65 72 (Pubitemid 47012080)
30. Wedge S. R., Kendrew J., Hennequin L. F., Valentine P. J., Barry S. T., Brave S. R., Smith N. R., James N. H., Dukes M., Curwen J. O., Chester R., Jackson J. A., Boffey S. J., Kilburn L. L., Barnett S., Richmond G. H. P., Wadsworth P. F., Walker M., Bigley A. L., Taylor S. T., Cooper L., Beck S., Jrgensmeier J. M., Ogilvie D. J., AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Research 2005 65 10 4389 4400 (Pubitemid 40775678)
31. Bozec A., Sudaka A., Fischel J. L., Brunstein M. C., Etienne-Grimaldi M. C., Milano G., Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model British Journal of Cancer 2008 99 1 93 99 (Pubitemid 351920227)
32. Bozec A., Sudaka A., Toussan N., Fischel J. L., Etienne-Grimaldi M. C., Milano G., Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model Annals of Oncology 2009 20 10 1703 1707
33. Myoung H., Hong S. D., Kim Y. Y., Hong S. P., Kim M. J., Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma Cancer Letters 2001 163 2 191 200 (Pubitemid 32126365)
34. D'Amato R. J., Loughnan M. J., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085 (Pubitemid 24139577)
35. Kenyon B. M., Browne F., D'Amato R. J., Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Experimental Eye Research 1997 64 6 971 978 (Pubitemid 27314772)
36. Kruse F. E., Joussen A. M., Rohrschneider K., Becker M. D., Vlcker E., Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor Graefe's Archive for Clinical and Experimental Ophthalmology 1998 236 6 461 466 (Pubitemid 28269042)
37. Verheul H. M., Panigrahy D., Yuan J., D'Amato R. J., Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits British Journal of Cancer 1999 79 1 114 118 (Pubitemid 28566935)
38. Burt H. M., Jackson J. K., Bains S. K., Liggins R. T., Oktaba A. M. C., Arsenault A. L., Hunter W. L., Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid) Cancer Letters 1995 88 1 73 79
39. Dordunoo S. K., Jackson J. K., Arsenault L. A., Oktaba A. M., Hunter W. L., Burt H. M., Taxol encapsulation in poly( -caprolactone) microspheres Cancer Chemotherapy and Pharmacology 1995 36 4 279 282
40. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M. R., Viale G., Giavazzi R., Taraboletti G., The microtubule-affecting drug paclitaxel has antiangiogenic activity Clinical Cancer Research 1996 2 11 1843 1849 (Pubitemid 26384151)
41. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R. J., Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol Cancer Research 1997 57 1 81 86 (Pubitemid 27021522)
42. Choong N. W., Kozloff M., Taber M., Hu H. S., Wade J., Ivy P., Karrison T. G., Dekker A., Vokes E. E., Cohen E. E. W., Phase II study of sunitinib malate in head and neck squamous cell carcinoma Investigational New Drugs 2010 28 5 677 683
43. Fountzilas G., Fragkoulidi A., Kalogera-Fountzila A., Nikolaidou M., Bobos M., Calderaro J., Andreiuolo F., Marselos M., A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer Cancer Chemotherapy and Pharmacology 2010 65 4 649 660
44. Machiels J.-P. H., Henry S., Zanetta S., Kaminsky M. C., Michoux N., Rommel D., Schmitz S., Bompas E., Dillies A. -F., Faivre S., Moxhon A., Duprez T., Guigay J., Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01 Journal of Clinical Oncology 2010 28 1 21 28
45. Elser C., Siu L. L., Winquist E., Agulnik M., Pond G. R., Chin S. F., Francis P., Cheiken R., Elting J., McNabola A., Wilkie D., Petrenciuc O., Chen E. X., Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma Journal of Clinical Oncology 2007 25 24 3766 3772
46. Williamson S. K., Moon J., Huang C. H., Guaglianone P. P., LeBlanc M., Wolf G. T., Urba S. G., Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: southwest Oncology Group Study S0420 Journal of Clinical Oncology 2010 28 20 3330 3335
47. Cohen E. W., Davis D. W., Karrison T. J., Seiwert T. Y., Wong S. J., Nattam S., Kozloff M. F., Clark J. I., Yan D. H., Liu W., Pierce C., Dancey J. E., Stenson K., Blair E., Dekker A., Vokes E. E., Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study The Lancet Oncology 2009 10 3 247 257
48. Ciardiello F., Bianco R., Damiano V., Fontanini G., Caputo R., Pomatico G., De Placido S., Bianco A. R., Mendelsohn J., Tortora G., Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clinical Cancer Research 2000 6 9 3739 3747
49. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J. M., Rak J., Kerbel R. S., Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Research 2001 61 13 5090 5101 (Pubitemid 32681540)
50. Ciardiello F., Bianco R., Caputo R., Caputo R., Damiano V., Troiani T., Melisi D., De Vita F., De Placido S., Bianco A. R., Tortora G., Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clinical Cancer Research 2004 10 2 784 793 (Pubitemid 38174017)
51. Herbst R. S., O'Neill V. J., Fehrenbacher L., Belani C. P., Bonomi P. D., Hart L., Melnyk O., Ramies D., Lin M., Sandler A., Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer Journal of Clinical Oncology 2007 25 30 4743 4750 (Pubitemid 350086476)
52. Saltz L. B., Lenz H. J., Kindler H. L., Hochster H. S., Wadler S., Hoff P. M., Kemeny N. E., Hollywood E. M., Gonen M., Quinones M., Morse M., Chen H. X., Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study Journal of Clinical Oncology 2007 25 29 4557 4561 (Pubitemid 350035312)
53. Prichard C. N., Kim S., Yazici Y. D., Doan D. D., Jasser S. A., Mandal M., Myers J. N., Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma Laryngoscope 2007 117 4 674 679 (Pubitemid 46559046)
54. Seiwert T. Y., Haraf D. J., Cohen E. W., Stenson K., Witt M. E., Dekker A., Kocherginsky M., Weichselbaum R. R., Chen H. X., Vokes E. E., Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer Journal of Clinical Oncology 2008 28 10 1732 1741
55. Salama J. K., Vokes E. E., Chmura S. J., Milano M. T., Kao J., Stenson K. M., Witt M. E., Haraf D. J., Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma International Journal of Radiation Oncology Biology Physics 2006 64 2 382 391 (Pubitemid 43083422)
56. Spencer S. A., Harris J., Wheeler R. H., Machtay M., Schultz C., Spanos W., Rotman M., Meredith R., RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck International Journal of Radiation Oncology Biology Physics 2001 51 5 1299 1304 (Pubitemid 33116324)
57. Vokes E. E., Panje W. R., Schilsky R. L., Mick R., Awan A. M., Moran W. J., Goldman M. D., Tybor A. G., Weichselbaum R. R., Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study Journal of Clinical Oncology 1989 7 6 761 768 (Pubitemid 19145598)
58. Haraf D. J., Weichselbaum R. R., Yokes E. E., Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease Annals of Oncology 1996 7 9 913 918 (Pubitemid 26426265)
59. Brockstein B., Haraf D. J., Stenson K., Fasanmade A., Stupp R., Glisson B., Lippman S. M., Ratain M. J., Sulzen L., Klepsch A., Weichselbaum R. R., Vokes E. E., Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck Journal of Clinical Oncology 1998 16 2 735 744 (Pubitemid 28135623)
60. Vokes E. E., Haraf D. J., Mick R., McEvilly J. M., Weichselbaum R. R., Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer Journal of Clinical Oncology 1994 12 11 2351 2359 (Pubitemid 24346707)
61. Brockstein B., Haraf D. J., Stenson K., Sulzen L., Witt M. E., Weichselbaum R. W., Vokes E. E., A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer Annals of Oncology 2000 11 6 721 728
62. Salama J. K., Haraf D. J., Stenson K., Milano M. T., Witt M. E., Vokes E. E., Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer Cancer Journal 2005 11 2 140 146 (Pubitemid 44698825)
63. Milano M. T., Haraf D. J., Stenson K. M., Witt M. E., Eng C., Mittal B. B., Argiris A., Pelzer H., Kozloff M. F., Vokes E. E., Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck Clinical Cancer Research 2004 10 15 4922 4932 (Pubitemid 39099765)
64. de Crevoisier R., Domenge C., Wibault P., Koscielny S., Lusinchi A., Janot F., Bobin S., Luboinski B., Eschwege F., Bourhis J., Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma Cancer 2001 91 11 2071 2076 (Pubitemid 32476371)
65. de Crevoisier R., Bourhis J., Domenge C., Wibault P., Koscielny S., Lusinchi A., Mamelle G., Janot F., Julieron M., Leridant A. M., Marandas P., Armand J. P., Schwaab G., Luboinski B., Eschwege F., Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients Journal of Clinical Oncology 1998 16 11 3556 3562 (Pubitemid 28506768)
66. Spencer S. A., Wheeler R. H., Peters G. E., Beenken S. W., Meredith R. F., Smith J., Conner W., Salter M. M., Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck American Journal of Clinical Oncology 1999 22 1 1 5 (Pubitemid 30261579)
67. Spencer S. A., Harris J., Wheeler R. H., Machtay M., Schultz C., Spanos W., Rotman M., Meredith R., Ang K. -K., Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck Head and Neck 2008 30 3 281 288 (Pubitemid 351480742)
68. Meluch A. A., Spigel D., Burris H. A., Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck 27 Proceedings of the Annual Meeting of the American Society of Clinical Oncology (ASCO '09) May 2009 15S 6012
69. Pfister D. G., Lee N. Y., Sherman E., Phase II study of bevacizumab (B) plus cisplatin (C) plus intensity-modulated radiation therapy (IMRT) for locoregionally advanced head and neck squamous cell cancer (HNSCC): preliminary results 27 Proceedings of the Annual Meeting of the American Society of Clinical Oncology (ASCO '09) May 2009 15S 6013
70. Ebos J. M. L., Lee C. R., Cruz-Munoz W., Bjarnason J. A., Christensen J. G., Kerbel R. S., Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis Cancer Cell 2009 15 3 232 239
71. Pez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vials F., Inoue M., Bergers G., Hanahan D., Casanovas O., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 2009 15 3 220 231
72. Johannsen M., Florcken A., Bex A., Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre retrospective analysis European Urology 2009 55 6 1430 1438
73. Brahimi-Horn M. C., Chiche J., Pouysségur J., Hypoxia and cancer Journal of Molecular Medicine 2007 85 12 1301 1307 (Pubitemid 50004093)
74. Yu J. L., Rak J. W., Coomber B. L., Hicklin D. J., Kerbel R. S., Effect of p53 status on tumor response to antiangiogenic therapy Science 2002 295 5559 1526 1528 (Pubitemid 34174008)
75. Shaked Y., Ciarrocchi A., Franco M., Lee C. R., Man S., Cheung A. M., Hicklin D. J., Chaplin D., Foster F. S., Benezra R., Kerbel R. S., Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 2006 313 5794 1785 1787 (Pubitemid 44454154)
76. Condeelis J., Pollard J. W., Macrophages: obligate partners for tumor cell migration, invasion, and metastasis Cell 2006 124 2 263 266 (Pubitemid 43121975)
77. Nozawa H., Chiu C., Hanahan D., Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis Proceedings of the National Academy of Sciences of the United States of America 2006 103 33 12493 12498 (Pubitemid 44267286)
78. Kerbel R. S., Tumor angiogenesis New England Journal of Medicine 2008 358 19 2039 2049 (Pubitemid 351656458)
79. Joyce J., Pollard J. W., Microenvironmental regulation of metastasis Nature Reviews Cancer 2009 9 4 239 252
80. de Palma M., Venneri M. A., Galli R., Sergi L. S., Politi L. S., Sampaolesi M., Naldini L., Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors Cancer Cell 2005 8 3 211 226 (Pubitemid 41317592)
81. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., Hicklin D. J., Zhu Z., Bohlen P., Witte L., Hendrikx J., Hackett N. R., Crystal R. G., Moore M. A. S., Werb Z., Lyden D., Rafii S., Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment Nature Medicine 2002 8 8 841 849
82. Kaplan R. N., Riba R. D., Zacharoulis S., Bramley A. H., Vincent L., Costa C., MacDonald D. D., Jin D. K., Shido K., Kerns S. A., Zhu Z., Hicklin D., Wu Y., Port J. L., Altorki N., Port E. R., Ruggero D., Shmelkov S. V., Jensen K. K., Rafii S., Lyden D., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 2005 438 7069 820 827 (Pubitemid 41753060)
83. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Yung S., Chimenti S., Landsman L., Abramovitch R., Keshet E., VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells Cell 2006 124 1 175 189 (Pubitemid 43069318)
84. Du R., Lu K. V., Petritsch C., Liu P., Ganss R., Passegué E., Song H., VandenBerg S., Johnson R. S., Werb Z., Bergers G., HIF1 induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion Cancer Cell 2008 13 3 206 220 (Pubitemid 351318372)
85. Shojaei F., Wu X., Malik A. K., Zhong C., Baldwin M. E., Schanz S., Fuh G., Gerber H. P., Ferrara N., Tumor refractoriness to anti-VEGF treatment is mediated by CD11b +Gr1+ myeloid cells Nature Biotechnology 2007 25 8 911 920 (Pubitemid 47236916)
86. Shojaei F., Singh M., Thompson J. D., Ferrara N., Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression Proceedings of the National Academy of Sciences of the United States of America 2008 105 7 2640 2645 (Pubitemid 351520566)
87. Ebos J. M., Lee C. R., Christensen J. G., Mutsaers A. J., Kerbel R. S., Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proceedings of the National Academy of Sciences of the United States of America 2007 104 43 17069 17074 (Pubitemid 350210993)
88. Bergers G., Hanahan D., Modes of resistance to anti-angiogenic therapy Nature Reviews Cancer 2008 8 8 592 603